Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

• Published in: Cancer research communications Vol. 4; no. 3; pp. 757 - 764
• Main Authors: Keller, Alana L, Reiman, Lauren T, Perez de Acha, Olivia, Parzych, Sarah E, Forsberg, Peter A, Kim, Peter S, Bisht, Kamlesh, Wang, Hongfang, van de Velde, Helgi, Sherbenou, Daniel W
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 12.03.2024
• Subjects: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Agents - therapeutic use; B-Cell Maturation Antigen - therapeutic use; Drug Mechanisms; Drug Resistance; Drug Targets; Hematological Cancers; Humans; Immunotherapy; Multiple Myeloma - drug therapy; Neoplasm Recurrence, Local - drug therapy; Preclinical Models; T-Lymphocytes
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-23-0434

T cell-engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even in patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with multiple myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) for ex vivo measurement of anti-multiple myeloma cytotoxicity for the trispecific CD38/CD28xCD3 TCE SAR442257 through activation of the patients' own endogenous T cells to inform clinical development of the compound in multiple myeloma. My-DST incubates primary mononuclear cells in humanized media for 48 hours followed by flow cytometry for multiple myeloma cell viability with or without drug treatment. SAR442257 was tested on 34 samples from patients with multiple myeloma across disease settings. Potential biomarkers, T-cell dependence, and degranulation were assessed. SAR442257 was effective at low dose in My-DST cultures. High ex vivo response rates were observed in primary aspirates taken from patients with multiple myeloma at diagnosis, with modestly reduced response in multiple myeloma recently treated with anti-CD38 mAbs. SAR442257 was highly effective in patients relapsing after BCMA therapy. The CD38/CD28xCD3 trispecific format was substantially more effective than a conventional bispecific CD38/CD3 antibody format and CD38 mAbs. Anti-multiple myeloma cell cytotoxicity was dependent on the presence of endogenous T cells. Surface CD38 expression was the strongest biomarker of TCE response. My-DST is capable of measuring T cell-dependent killing using the multiple myeloma patient's own bone marrow-derived T cells. SAR442257 shows promise for multiple myeloma and may be best suited for patients declared resistant to both CD38 mAbs and BCMA-targeted therapy. This study introduces the use of My-DST to measure and characterize sensitivity to anti-CD38 T-cell engager SAR442257 in primary samples using matched endogenous T cells. Preclinical testing in samples from patients with diverse treatment history supports further testing in post-chimeric antigen receptor T-cell multiple myeloma.